LCS
AZN icon

Levin Capital Strategies’s AstraZeneca AZN Stock Holding History

Levin Capital Strategies’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,000
Closed -$203K – 313
2017
Q3 		$203K Buy
+3,000
New +$190K ﹤0.01% 311
2014
Q4 		– Sell
-4,000
Closed -$286K – 387
2014
Q3 		$286K Buy
+4,000
New +$293K ﹤0.01% 301

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Levin Capital Strategies's AZN Position: Q4 2017 in Review

Levin Capital Strategies sold out of AstraZeneca (AZN) in Q4 2017, closing a stake of 3,000 shares — an estimated $203K sold.

Levin Capital Strategies first reported a position in AZN in Q3 2014 and held it in 2 quarters. The position peaked at $286K in Q3 2014. 503 funds tracked by Wall St. Rank hold AZN as of Q4 2017.

  • Levin Capital Strategies reported no remaining AstraZeneca position as of Q4 2017 after selling out during the quarter.
  • Levin Capital Strategies sold 3,000 AstraZeneca shares in Q4 2017, an estimated $203K.
  • Levin Capital Strategies first reported a position in AstraZeneca in Q3 2014 and held it in 2 quarters.
  • Levin Capital Strategies's AstraZeneca position peaked at $286K in Q3 2014.
  • 503 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2017.

Based on Levin Capital Strategies's 13F filing for Q4 2017, filed 9 Feb 2018.